ライフサイエンスコーパス: interleukin-1

1 ory cytokines like tumor necrosis factor and interleukin-1.

2 Interleukin-1 alpha (IL-1alpha) was increased in broncho

3 y cytokines, including TNF-alpha, IL-1alpha (Interleukin-1 alpha), RANTES (regulated on activation, n

4 ve circuit by upregulating and releasing the interleukin-1 analog Spatzle, which then acts on Toll re

5 specific for LMP1 and differs from TNFalpha, Interleukin-1 and CD40 signaling.

6 se is driven by the proinflammatory cytokine interleukin-1 and is known to exacerbate resulting injur

7 onditions were studied in chondrocytes using interleukin-1 and osteoarthritic synovial fluid.

8 y the much lower expression of receptors for interleukin-1 and TGFbeta, downstream protumor factors,

9 ession of proinflammatory cytokines (such as interleukin-1 and tumor necrosis factor-alpha) and chemo

10 ide primarily protects mice by repressing an interleukin-1- and 12/15-lipoxygenase-dependent neutroph

11 bant (bradykinin-B2-antagonist) or anakinra (interleukin-1-antagonist) reduces disease activity in pa

12 Here we tested polymorphisms of interleukin 1 beta (IL1B) and interleukin 1 receptor ant

13 duction of inflammation and up-regulation of interleukin 1 beta (IL1B) and matrix metalloproteinase (

14 Interleukin 1 beta (IL1B) increases intestinal permeabil

15 endently in human astrocytes by the cytokine interleukin 1 beta (IL1B), and inactivation of Vegfa in

16 data on the association between SNPs in the interleukin 1 beta gene (IL1B) and colorectal cancer (CR

17 or) cells in L2-IL1B mice (which overexpress interleukin 1 beta in esophagus and squamous forestomach

18 nomodulatory effects of PG-1 via stimulating interleukin 1 beta secretion.

19 lation of the neuroimmunomodulating cytokine interleukin 1 beta.

20 ogehrelin, selenium binding protein 1(SBP1), Interleukin-1 beta (IL-1beta) and Recombination-Activati

21 ion and stimulated the inflammatory cytokine interleukin-1 beta (IL-1beta) and the immunosuppressive

22 es of monocytes demonstrated upregulation of interleukin-1 beta (IL-1beta) and tumor necrosis factor

23 and clinical evidence reviewed here support interleukin-1 beta (IL-1beta) as both a local vascular a

24 Interleukin-1 beta (IL-1beta) is a pleiotropic mediator

25 Interleukin-1 beta (IL-1beta) is an inflammatory cytokin

26 Interleukin-1 beta (IL-1beta) is an inflammatory cytokin

27 inflammation-associated diseases by inducing interleukin-1 beta (IL-1beta) secretion.

28 n of either MYD88, IRAK4, or IRAK1 abolished interleukin-1 beta (IL-1beta) signaling; however, we wer

29 matory interleukin-6 (IL-6) expression after interleukin-1 beta (IL-1beta) stimulation.

30 tor-alpha (TNF-alpha), interleukin-6 (IL-6), interleukin-1 beta (IL-1beta), and monocyte chemo attrac

31 ation analyzed the proinflammatory cytokines interleukin-1 beta (IL-1beta), interleukin-6 (IL-6), and

32 , including aryl hydrocarbon receptor (Ahr), interleukin-1 beta (Il1b), estrogen receptor alpha (Esr1

33 n to activity levels through enhanced muscle interleukin-1 beta (IL1beta)/IL1 receptor signaling to g

34 e human cytokine proteins (interferon gamma, interleukin-1 beta, and tumor necrosis factor alpha) wer

35 ading depolarization such as upregulation of interleukin-1 beta, inducible nitric oxide synthase and

36 e release of tumor necrosis factor-alpha and interleukin-1 beta, which are pro-inflammatory cytokines

37 after exposure to the inflammatory cytokine interleukin-1 beta.

38 y, we describe how the inflammatory cytokine interleukin 1-beta (IL-1beta) rapidly affects protein tr

39 juvants.In vitro, these compounds induced an interleukin 1-beta (IL-1beta) response in the macrophage

40 demonstrate that NLRP3 inflammasome-mediated interleukin-1-beta (IL1beta) signaling drives HSPC produ

41 Interleukin-1 blockade has been utilized to treat system

42 ical and experimental evidence suggests that interleukin-1 blockade is effective against myocardial i

43 should be undertaken to confirm the role of interleukin-1 blockage.

44 tricles, inversely associated to CRP and IL (interleukin)-1 changes in acute infection patients.

45 for activation of the potent proinflammatory interleukin-1 cytokine family.

46 tumour slices results in an upregulation of interleukin-1 cytokines, an effect that is absent in co-

47 Genes at the locus include several interleukin 1 family members with roles in pro-inflammat

48 The interleukin 1 family plays an important role in the immu

49 Caspase-1 mediates the production of interleukin-1 family cytokines (IL1FCs), leading to feve

50 te immunity (most notably for members of the interleukin-1 family), which depend on the specific infl

51 lammatory mediators include cytokines of the interleukin-1 family, such as IL-1alpha and IL-1beta.

52 Interleukin-1 has been implicated as a mediator of recur

53 D (controls), we measured soluble markers of interleukin 1 (IL-1) activation at 4 different time poin

54 The roles of the interleukin 1 (IL-1) and interleukin 18 pathways in host

55 cells and by mitigating the cytotoxicity of interleukin 1 (IL-1) and tumor necrosis factor-alpha (TN

56 Within the interleukin 1 (IL-1) cytokine family, IL-1 receptor acce

57 Although interleukin 1 (IL-1) induces expression of the transcrip

58 Interleukin 1 (IL-1) is a major mediator for inflammatio

59 d to IL-1beta due to their low expression of interleukin 1 (IL-1) receptor 1 and high expression of t

60 his process and studied the role of the Toll/interleukin 1 (IL-1) receptor adapter and major inflamma

61 nt of bacterial clearance, deficiency in the interleukin 1 (IL-1) receptor led to a significant impai

62 Interleukin 1 (IL-1) receptor-associated kinases (IRAKs)

63 ion of macrophage inflammatory signaling and interleukin 1 (IL-1) signaling, which attenuates the acu

64 tokines such as tumor necrosis factor (TNF), interleukin 1 (IL-1), and interleukin 6 (IL-6).

65 N2 gene expression by ELF3 in the context of interleukin 1 (IL-1)-driven inflammatory responses in ch

66 olecule in inflammatory pathways involved in interleukin 1 (IL-1)/IL-18/Toll-like receptor signaling

67 Toll-like receptors (TLRs) and receptors for interleukin 1 (IL-1Rs) and to whole pathogens.

68 for an iron-responsive element (IRE) and an interleukin-1 (IL-1) acute box element.

69 nce suggests that pro-inflammatory cytokines interleukin-1 (IL-1) and IL-18 show an age-dependent reg

70 Interleukin-1 (IL-1) and the IL-1 receptor (IL-1R) famil

71 of various proinflammatory cytokines such as interleukin-1 (IL-1) and tumor necrosis factor-alpha, th

72 to optimize combined anti-CD3 treatment plus interleukin-1 (IL-1) blockade to reverse new-onset disea

73 ion often termed a "cytokine storm." Because interleukin-1 (IL-1) blocks the production of IL-6 and o

74 duces inflammasome activation and release of interleukin-1 (IL-1) cytokines.

75 The interleukin-1 (IL-1) family cytokines are cytosolic prot

76 ed the inflammasome, leading to secretion of interleukin-1 (IL-1) family cytokines, pyroptosis, and c

77 cholesterol (25-HC) overproduce inflammatory interleukin-1 (IL-1) family cytokines.

78 Cytokines of the interleukin-1 (IL-1) family induce inflammation and regu

79 ead to caspase activation and release of the interleukin-1 (IL-1) family members, IL-1beta and IL-18.

80 of obesity, with elevated cytokines such as interleukin-1 (IL-1) in the circulation and tissues.

81 Interleukin-1 (IL-1) is a key mediator of inflammation a

82 Interleukin-1 (IL-1) is a large cytokine family closely

83 Forty years after its naming, interleukin-1 (IL-1) is experiencing a renaissance broug

84 Interleukin-1 (IL-1) is implicated in numerous pathologi

85 sion of the pivotal proinflammatory cytokine interleukin-1 (IL-1) is increased in CML bone marrow.

86 Interleukin-1 (IL-1) mediates diverse neurophysiological

87 ced proinflammatory cytokines in response to interleukin-1 (IL-1) or tumor necrosis factor alpha (TNF

88 Here, we report that disruption of the interleukin-1 (IL-1) pathway completely uncouples the SA

89 generation as well as caspase-8 activity and interleukin-1 (IL-1) production.

90 Overexpression of several markers such as interleukin-1 (IL-1) receptor accessory protein (IL1RAP)

91 Further, we show that lack of interleukin-1 (IL-1) receptor attenuates gammaherpesviru

92 esponding normal cells, express a functional interleukin-1 (IL-1) receptor complex and respond with N

93 g K63-linked polyubiquitination of Pelle, an interleukin-1 (IL-1) receptor-associated kinase homolog

94 oss induced tumor necrosis factor (TNF)- and interleukin-1 (IL-1) receptor-dependent activation of st

95 ase that functions to prevent autoimmune and interleukin-1 (IL-1) receptor-dependent, caspase-1-indep

96 uction downstream of Toll-like receptors and interleukin-1 (IL-1) receptors.

97 ic brain injury, and to evaluate the role of interleukin-1 (IL-1) signaling as a target for pharmacol

98 Interleukin-1 (IL-1) signaling in fibroblasts is mediate

99 Interleukin-1 (IL-1) signaling is important for multiple

100 ects of stress are associated with increased interleukin-1 (IL-1) signaling within the central nervou

101 ase (IKK)/NF-kappaB signaling in response to interleukin-1 (IL-1) stimulation.

102 Genetic deletion of interleukin-1 (IL-1) using IL-1alphabeta knockout (KO) m

103 DCs are defined by their ability to release interleukin-1 (IL-1) while maintaining cell viability, e

104 Interleukin-1 (IL-1), an important proinflammatory cytok

105 the most important target classes, including interleukin-1 (IL-1), tumor necrosis factor alpha (TNF-a

106 Consistent with in vitro experiments, interleukin-1 (IL-1)-dependent autoantibody-mediated art

107 lar organizing centers that operate to drive interleukin-1 (IL-1)-dependent inflammation.

108 s, Legionella-infected macrophages induce an interleukin-1 (IL-1)-dependent inflammatory cytokine res

109 Pathogenic variants in two interleukin-1 (IL-1)-regulating genes, NLRP3 and IL1RN,

110 ECM) degradation, cells were co-treated with interleukin-1 (IL-1).

111 r molecule that mediates the TNFR family and interleukin-1 (IL-1)/Toll-like receptor (TLR) signaling

112 easing tumor necrosis factor (TNF-alpha) and interleukin-1 (IL-1beta) and thereby mimicking the chron

113 ls), and measured levels of cytokines of the interleukin 1 (IL1) family (IL1alpha, IL1beta, IL1ra, an

114 ory status epilepticus, with the recombinant interleukin-1 (IL1) receptor antagonist (IL1RA) anakinra

115 ow (BM) via a type II interferon (IFN-II) or interleukin-1 (IL1) response, respectively, which confer

116 ption of IFNB1 but not of the genes encoding interleukin-1 (IL1), interleukin-6 (IL6), or tumor necro

117 g to a role for the proinflammatory cytokine interleukin-1 in myocardial inflammation and contractile

118 isplatin, GTPgammaS, or the cytokines TNF or interleukin-1 increased STING-dependent IFN response to

119 Interleukin-1 induces the expression of miR-3085-3p, at

120 Interleukin-1 inhibition causes a greater improvement in

121 on of cardiac function responded promptly to interleukin-1 inhibition.

122 ) diffusion of the pro-inflammatory cytokine interleukin-1 into tissue, and (2) the effect of excessi

123 Inhibition of interleukin 1 is a promising treatment strategy.

124 Interleukin-1 is an important mediator of cartilage dest

125 The activity of interleukin-1 is regulated by multimolecular protein com

126 Genetic ablation of interleukin-1 ligands or receptor in mice bearing RCAS/t

127 hway for enriched ICs was lipopolysaccharide/Interleukin 1 mediated inhibition of Retinoid X Receptor

128 tumor resection, and many were prevented by interleukin-1 or granulocyte colony-stimulating factor b

129 increased macrophage inflammatory protein 1, interleukin-1, P-selectin, cluster of differentiation 45

130 Here we show that hyperactivation of the interleukin 1 pathway, through either ablation of the in

131 re, we demonstrate that dexamethasone blocks interleukin-1 production in both bone marrow-derived and

132 h their role in Toll-like receptor (TLR) and interleukin 1 receptor (IL-1R) mediated signaling pathwa

133 LLIP) regulates Toll-like receptor (TLR) and interleukin 1 receptor (IL-1R) signaling against mycobac

134 DA-5), as well as cytokine receptors such as interleukin 1 receptor (IL-1R), have been implicated in

135 Single immunoglobulin and toll-interleukin 1 receptor (SIGIRR), a negative regulator of

136 n primary response gene 88 (MyD88)- and Toll-interleukin 1 receptor (TIR) domain-containing adaptor i

137 Here, we describe a Toll/interleukin 1 receptor (TIR) domain-containing protein (

138 SENSITIVE 3 (CHS3) encodes an atypical Toll/Interleukin 1 Receptor (TIR)-type NLR protein with an ad

139 or the upstream mediator of its expression, interleukin 1 receptor 1.

140 in 1 pathway, through either ablation of the interleukin 1 receptor 8 (IL-1R8, also known as SIGIRR o

141 The interleukin 1 receptor accessory protein (IL1RAP; IL1R3)

142 IRAK-4 and MyD88 deficiencies impair interleukin 1 receptor and Toll-like receptor (TLR) sign

143 h rituximab alone, increased serum IL-12 and interleukin 1 receptor antagonist (IL-1RA) (P = .005 and

144 Serum interleukin 1 receptor antagonist (IL-1RA) levels were e

145 lymorphisms of interleukin 1 beta (IL1B) and interleukin 1 receptor antagonist (IL1RA) genes for asso

146 d P = .00005 for IMI, by the log-rank test), interleukin 1 receptor antagonist (IL1RN; rs419598; P =

147 Finally, inclusion of interleukin 1 receptor antagonist (Kineret(R)) in the ad

148 sis revealed an inverse relationship between interleukin 1 receptor antagonist and colony-stimulating

149 itric oxide synthase, interleukin-1beta, and interleukin 1 receptor antagonist but not transforming g

150 roglial numbers, increased interleukin 6 and interleukin 1 receptor antagonist messenger RNA, alterat

151 Finally, early acute levels of interleukin 1 receptor antagonist were associated with t

152 lts showed a significant increase in IL-1RA (interleukin 1 receptor antagonist) mRNA expression and a

153 ectrin breakdown product 150, interleukin 6, interleukin 1 receptor antagonist, and c-reactive protei

154 in 6, granulocyte colony-stimulating factor, interleukin 1 receptor antagonist, and vascular endothel

155 Potential immune markers, including interleukin 1 receptor antagonist, interferon gamma-indu

156 le nucleotide polymorphism A471T in the Toll-interleukin 1 receptor domain (TIR) of the IL-1Rrp2 that

157 ctivate downstream signaling via TIRAP (Toll-interleukin 1 receptor domain containing adaptor protein

158 Toll-interleukin 1 receptor domain NLRs (TNLs) converge on th

159 ne spanning region and an intracellular Toll/Interleukin 1 receptor domain which invokes signal trans

160 with mice lacking signaling through the Toll-Interleukin 1 Receptor Domain-Containing Adaptor Protein

161 rimary response protein 88 (MyD88), and Toll interleukin 1 receptor domain-containing adaptor protein

162 ied the expression of IL36 and its receptor, interleukin 1 receptor like 2 (IL1RL2 or IL36R) in the d

163 terleukin-1beta interacts with its receptor (interleukin 1 receptor type 1) on hematopoietic stem and

164 IC associated genes included the innate interleukin 1 receptor, type 1 and the antimicrobial pep

165 n primary murine macrophages, dependent upon interleukin 1 receptor-associated kinase (IRAK-1).

166 mammals and overlaps with the 5' UTR of the interleukin 1 receptor-associated kinase (IRAK1) gene.

167 This included a Phe196Ser change in the interleukin 1 receptor-associated kinase 1 (IRAK1).

168 ma infection than wild-type, Dectin-1-/-, or interleukin 1 receptor-deficient (IL-1R-/-) mice.

169 Interleukin 1 receptor-like 1 (IL1RL1), also known as su

170 on of IRAK1, a kinase thus far implicated in interleukin-1 receptor (IL-1R) and Toll-like receptor (T

171 nown that TLR3 uses the adaptor protein Toll/interleukin-1 receptor (IL-1R) domain-containing adaptor

172 members of the Toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) families transduce signal

173 We found that Toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling dynamics relied

174 ), a negative regulator of the Toll-like and interleukin-1 receptor (IL-1R) signaling pathways, contr

175 e expression of the Toll-like receptor (TLR)/interleukin-1 receptor (IL-1R) superfamily, IL-1beta pro

176 ting microglia expressed high amounts of the interleukin-1 receptor (IL-1R), and treatment with an IL

177 c expression of toll-like receptor 4 (TLR4), interleukin-1 receptor (IL-1R), or interferon-gamma rece

178 inhibitors to assess the regulatory roles of interleukin-1 receptor (IL-1R)-associated kinase 4 (IRAK

179 fied nearly two decades ago as a mediator of interleukin-1 receptor (IL-1R)-mediated activation of NF

180 fied roles in IFN-I stimulation for the Toll-interleukin-1 receptor (TIR) adaptor Myd88 adaptor-like

181 plementation, and found that C15 in the Toll/interleukin-1 receptor (TIR) domain and L816 in the LRR

182 ve to Nicotiana benthamiana with a Toll-like interleukin-1 receptor (TIR) domain bound to the Xanthom

183 neurodegenerative process(5-8), and its Toll/interleukin-1 receptor (TIR) domain exerts its pro-neuro

184 Herein, by using the toll/interleukin-1 receptor (TIR) domain homologous C-termina

185 rly Leu265Pro (L265P), within the MyD88 Toll/interleukin-1 receptor (TIR) domain sustain lymphoma cel

186 e-rich repeat (NLR) protein with a Toll-like interleukin-1 receptor (TIR) domain, which mediates XopQ

187 lipopolysaccharide, this is a delayed, Toll/interleukin-1 receptor (TIR) domain-containing adapter-i

188 esponses by targeted degradation of the Toll/interleukin-1 receptor (TIR) domain-containing adaptor p

189 L6 is a Toll/interleukin-1 receptor (TIR) domain-containing NLR from

190 ults in dimerization of their cytosolic Toll/interleukin-1 receptor (TIR) domains and recruitment of

191 oth processes depend on closely related Toll/interleukin-1 receptor (TIR) domains in these proteins,

192 We demonstrate that plant Toll/interleukin-1 receptor (TIR) domains of NLRs are enzymes

193 Toll-like receptors (TLRs), cytoplasmic Toll/interleukin-1 receptor (TIR) domains of the receptors un

194 aling adapter protein interactions with Toll/Interleukin-1 Receptor (TIR) domains present in sensory

195 Analysis of Toll/interleukin-1 receptor (TIR) sequences indicated that th

196 structures of MAL revealed a nontypical Toll/interleukin-1 receptor (TIR)-domain fold stabilized by t

197 equires the P loops of each protein and Toll/interleukin-1 receptor (TIR)-domain-mediated heteromeric

198 In this study, we identified interleukin-1 receptor 1 (IL1R1) as a mediator of celast

199 Interleukin-1 receptor 8 (IL-1R8, also known as single i

200 D88(-/-), MyD88/TLR adaptor molecule 1(-/-), interleukin-1 receptor [IL-1R1](-/-), and interleukin (I

201 Interleukin-1 receptor accessory protein (IL1RAP; IL1R3)

202 Mutations and deletions of the interleukin-1 receptor accessory protein like 1 (IL1RAPL

203 the X-linked intellectual disability protein interleukin-1 receptor accessory protein like 1 (IL1RAPL

204 E) epsilon4 status was identified in IL1RAP (interleukin-1 receptor accessory protein; rs12053868-G;

205 ndings broaden our understanding of how Toll/interleukin-1 receptor adaptor proteins may participate

206 TLR2 and TLR4 signal via the Toll/interleukin-1 receptor adaptors MyD88 and MAL, leading t

207 t of T2D, including the inflammation markers interleukin-1 receptor agonist (IL-1RA) and high-sensiti

208 Tear concentrations increased for interleukin-1 receptor antagonist (16 557.1 +/- 4047.8 v

209 10 kDa (IP-10) (53-fold) and an increase in interleukin-1 receptor antagonist (IL-1ra) (5-fold) were

210 itors enhance the anti-inflammatory cytokine interleukin-1 receptor antagonist (IL-1Ra) secretion in

211 Notably, the hepatic expression of interleukin-1 receptor antagonist (IL-1ra) was suppresse

212 The endogenous interleukin-1 receptor antagonist (IL-1Ra), an inflammat

213 culating levels of C-reactive protein (CRP), interleukin-1 receptor antagonist (IL-1Ra), and soluble

214 6), tumor necrosis factor-alpha (TNF-alpha), interleukin-1 receptor antagonist (IL-1RA), and transfor

215 single IFN target gene, Il1rn, which encodes interleukin-1 receptor antagonist (IL-1Ra), is sufficien

216 otype of the tumour through the secretion of interleukin-1 receptor antagonist (IL-1RA).

217 6], tumor necrosis factor-alpha [TNF-alpha], interleukin-1 receptor antagonist [IL-1RA], and transfor

218 D and confirmed six proteins (leptin, renin, interleukin-1 receptor antagonist [IL-1ra], hepatocyte g

219 ate immune system and chemotactic signaling (interleukin-1 receptor antagonist [IL-1Ra], IL-6, IL-8,

220 3), and antiinflammatory markers (increased interleukin-1 receptor antagonist and lower monocyte and

221 py efficacy stemmed from the upregulation of interleukin-1 receptor antagonist and suppression of MDS

222 ombinant activated protein C, talactoferrin, interleukin-1 receptor antagonist in sepsis, and muscle

223 ral infiltrates are associated with elevated interleukin-1 receptor antagonist or interleukin-8 and 2

224 l activation by minocycline or by transgenic interleukin-1 receptor antagonist overexpression rescued

225 in plasma interleukin-8, interleukin-10, and interleukin-1 receptor antagonist posttransfusion compar

226 akinra is a recombinant version of the human interleukin-1 receptor antagonist used to treat autoinfl

227 ling for age, gender, and primary diagnosis, interleukin-1 receptor antagonist was higher on study da

228 associated with augmented concentrations of interleukin-1 receptor antagonist, a key anti-inflammato

229 We investigated the effects of anakinra, an interleukin-1 receptor antagonist, on coronary and left

230 Component 1 (interleukin-1 receptor antagonist, QA, and kynurenine) w

231 ed growth factor receptors, and anakinra, an interleukin-1 receptor antagonist, respectively, increas

232 eating glutathione peroxidase 1 mice with an interleukin-1 receptor antagonist.

233 differentiation primary response 88 (MYD88)/interleukin-1 receptor associated kinase (IRAK) pathway,

234 88 L265P mutant results in the activation of interleukin-1 receptor associated kinase (IRAK).

235 a series of pyrrolopyrimidine inhibitors of interleukin-1 receptor associated kinase 4 (IRAK4) using

236 In this subgroup analysis, interleukin-1 receptor blockade was associated with sign

237 ctivation syndrome features may benefit from interleukin-1 receptor blockade.

238 entricular assist device, treatment with the interleukin-1 receptor blocking agent anakinra 100 mg/d

239 nt with fulminant viral myocarditis with the interleukin-1 receptor blocking agent anakinra.

240 ndicating that the Toll-6 receptor, the Toll/interleukin-1 receptor domain adaptor dSARM, and FoxO fu

241 cell line Mono Mac 6, induction of the Toll-interleukin-1 receptor domain-containing adaptor-inducin

242 production of ETs by S cells requires a Toll/Interleukin-1 receptor domain-containing protein TirA an

243 protein containing predicted lectin and Toll/Interleukin-1 receptor domains.

244 Four biomarkers, soluble form of ST2 (an interleukin-1 receptor family member), galectin-3, matri

245 The interleukin-1 receptor I (IL-1RI) is critical for host r

246 chemoattractant protein-1, resistin, soluble interleukin-1 receptor I, soluble interleukin-2 receptor

247 d deficiencies in the inflammatory response, interleukin-1 receptor knockout (IL-1R(-/-)) and caspase

248 -/-)), caspase-1 knockout (Casp-1(-/-)), and interleukin-1 receptor knockout (IL-1R(-/-)) mice treate

249 because deletion of Nlrp3, caspase-1 and the interleukin-1 receptor markedly protects against rheumat

250 Sterile alpha and Toll/interleukin-1 receptor motif-containing protein 1 (SARM1

251 in their N-terminal domains: these are Toll/interleukin-1 receptor resistance (TIR) domain-containin

252 In Toll-like receptor and interleukin-1 receptor signaling pathways, the kinase IR

253 mon adaptor for toll-like receptor (TLR) and Interleukin-1 receptor signaling, are critical for radio

254 rotein that mediates Toll-like receptors and interleukin-1 receptor signaling.

255 ucially relies on the Nlrp3 inflammasome and interleukin-1 receptor signalling.

256 nization, we show that mice deficient in the interleukin-1 receptor type 1 (Il1r1(-/-)) have reduced

257 y protein (IL1RAP; IL1R3) is a coreceptor of interleukin-1 receptor type 1 and has been found upregul

258 Interleukin-1 receptor type 2 (IL1R2) acts as a decoy re

259 Interleukin-1 receptor type I knockout mice, which displ

260 arized macrophages that highly expresses the interleukin-1 receptor, CD206 and interleukin-4 receptor

261 00 [UL = unique long]) and host-genes (e.g., interleukin-1 receptor, IRF1).

262 signalling (tumour necrosis factor receptor/interleukin-1 receptor, TNFR/IL-1R in mammals) is indisp

263 The 28-kDa form of IL-1beta cannot activate interleukin-1 receptor-1 (IL1R1) to signal inflammatory

264 to caspase proteolytic activity that cleaves interleukin-1 receptor-2, allowing IL-1alpha dissociatio

265 n assays show that IL-1alpha associates with interleukin-1 receptor-2, and this association is decrea

266 e residues in the known TLR pathway kinases, Interleukin-1 receptor-associated kinase (IRAK) 2 and IR

267 pathway involving the MyD88 adapter and the interleukin-1 receptor-associated kinase (IRAK) complex.

268 Here we report that interleukin-1 receptor-associated kinase 1 (IRAK1) is ov

269 use of TMP with Bruton's tyrosine kinase or interleukin-1 receptor-associated kinase 1 and 4 inhibit

270 rvival pathway, leading to downregulation of interleukin-1 receptor-associated kinase 1.

271 onse was reversed in the patient, but not in interleukin-1 receptor-associated kinase 4 (IRAK-4)-defi

272 Interleukin-1 receptor-associated kinase 4 (IRAK4) is a

273 Interleukin-1 receptor-associated kinase 4 (IRAK4) plays

274 Interleukin-1 receptor-associated kinase 4 (IRAK4) was t

275 ying very rare loss-of-function mutations in interleukin-1 receptor-associated kinase 4 (IRAK4), a cr

276 diminished degradation and interaction with interleukin-1 receptor-associated kinase 4 (IRAK4).

277 main containing adaptor protein)-MyD88-IRAK (interleukin-1 receptor-associated kinase)1/4-TRAF6 (TNF

278 Interleukin-1 receptor-associated kinase-1 (IRAK-1) and

279 gulating Lys-63-linked polyubiquitination of interleukin-1 receptor-associated kinase-1 (IRAK1) by th

280 A possible involvement of the gene IL1RAP (interleukin-1 receptor-associated protein) in the pathog

281 dipocyte differentiation, whereas Got2, Cpq, interleukin-1 receptor-like 1/ST2-IL-33, Sparc, and Lgal

282 mune receptors containing an N-terminal Toll-interleukin-1 receptor-like domain (TNLs) in Arabidopsis

283 n primary response 88 adaptors, but not toll/interleukin-1 receptor/resistance [TIR] domain-containin

284 We hypothesized that administration of IL-1 (interleukin-1) receptor antagonist (anakinra) could inhi

285 Interleukin-1-receptor-like-1 (IL1RL1 or ST2) is a well-

286 s the key signaling adapter of Toll-like and interleukin-1 receptors.

287 Both lipids induce caspase-11-dependent interleukin-1 release, but only LPS induces pyroptosis.

288 of monocytes/macrophages, granulocytes, and interleukin 1 signaling was investigated using depletion

289 Monocytes/macrophages and interleukin 1 signaling were required to protect trained

290 terleukin 1beta, suggesting a disturbance in interleukin 1 signaling.

291 differences in dendritic cell maturation and interleukin-1 signaling pathways and increased expressio

292 he stability of wild-type MLL in response to interleukin-1 signaling.

293 share therapeutic efficacies and establishes interleukin-1 signalling as an attractive and specific t

294 is shown to inhibit downstream effectors of interleukin-1 signalling in both macrophage populations.

295 Collectively, this evidence suggests that interleukin-1 signalling inhibition and dexamethasone tr

296 ture of systemic lupus erythematosus and the interleukin-1 signature in systemic onset juvenile idiop

297 f clinical response of sJIA and CAPS to anti-interleukin 1 therapies prompted a comparison at the bio

298 TGFbeta1 (transforming growth factor beta1), interleukin-1, TNF-alpha, and BDNF signaling pathways.

299 Fadd and Tnfsf9) and inflammatory (for, eg, interleukin 1, tumor necrosis factor alpha, chemokines,

300 d Nck1's proinflammatory role by identifying interleukin 1 type I receptor kinase-1 (IRAK-1) as a Nck